GlassScriptPhysician profile
Eric Jason Weinstein
NPI 1962534693
$4,070.55
in general payments reported to CMS, 2019-2025
32 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $444 · 2021: $48.63 · 2022: $577 · 2023: $1,172 · 2024: $380 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,003.34 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $505.79 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Genzyme Corporation | $431.51 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.33 | 2019-2024 | Ofev |
| Pulmonx Corporation | $227.33 | 2019-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Grifols USA, LLC | $184.60 | 2019-2024 | Prolastin-C Liquid |
| Ethicon INC. | $166.72 | 2024-2025 | Monarch Platform |
| Regeneron Healthcare Solutions, INC. | $161.88 | 2019-2023 | Dupixent |
| Mylan Specialty L.P. | $148.65 | 2019-2023 | Yupelri |
| Genentech USA, INC. | $132.89 | 2019-2023 | Xolair, Esbriet |
| Takeda Pharmaceuticals U.S.A., INC. | $91.97 | 2022-2024 | Glassia |
| Mayne Pharma Commercial LLC | $82.51 | 2019-2020 | |
| Astellas Pharma US INC | $76.98 | 2019-2020 | |
| Philips North America LLC | $61.26 | 2019-2023 | |
| Inogen, INC. | $46.90 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.77 | 2020-2023 | |
| Portola Pharmaceuticals, LLC | $42.52 | 2019-2020 | |
| Baxter Healthcare | $41.69 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $35.57 | 2023-2024 | Tezspire |
| Electromed, INC. | $35.22 | 2019-2023 | Smartvest |
| Advanced Respiratory, INC | $35.09 | 2019 | |
| Medical Device Business Services, INC. | $33.57 | 2024 | Monarch |
| Shockwave Medical, INC | $26.23 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Covis Pharma Gmbh | $25.19 | 2022 | |
| Medtronic, INC. | $23.27 | 2025 | Bis |
| Actelion Pharmaceuticals US, INC. | $20.64 | 2023 | Opsumit |
| Jazz Pharmaceuticals INC. | $18.80 | 2020 | |
| Veran Medical Technologies, INC. | $18.41 | 2019 | |
| Insmed, INC. | $17.79 | 2025 | Brinsupri, Arikayce |
| Haemonetics Corporation | $15.35 | 2022 | |
| Resmed Corp | $14.28 | 2023 | |
| United Therapeutics Corporation | $2.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.